Pulse Biosciences (NASDAQ:PLSE) Shares Up 9.4% – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price shot up 9.4% during mid-day trading on Monday . The company traded as high as $33.15 and last traded at $33.07. Approximately 166,997 shares were traded during trading, a decline of 50% from the average session volume of 332,235 shares. The stock had previously closed at $30.23.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PLSE shares. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Finally, Canaccord Genuity Group assumed coverage on shares of Pulse Biosciences in a research report on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.33.

Pulse Biosciences Price Performance

The firm has a market cap of $2.52 billion, a PE ratio of -32.54 and a beta of 1.65. The business has a fifty day moving average price of $27.11 and a two-hundred day moving average price of $22.41.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.25 million. As a group, sell-side analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Paul A. Laviolette purchased 15,000 shares of Pulse Biosciences stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at $295,350. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan purchased 660,233 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the acquisition, the director owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. This trade represents a 1.39% increase in their position. The SEC filing for this purchase provides additional information. 74.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences during the 2nd quarter worth about $158,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at about $215,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.